Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Receivables (2019 - 2024)

Revolution Medicines has reported Change in Receivables over the past 6 years, most recently at -$1.3 million for Q1 2024.

  • Quarterly results put Change in Receivables at -$1.3 million for Q1 2024, down 84.96% from a year ago — trailing twelve months through Dec 2024 was -$1.3 million (up 63.32% YoY), and the annual figure for FY2024 was -$1.3 million, up 63.32%.
  • Change in Receivables for Q1 2024 was -$1.3 million at Revolution Medicines, down from $945000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for RVMD hit a ceiling of $2.0 million in Q3 2020 and a floor of -$2.9 million in Q4 2020.
  • Median Change in Receivables over the past 5 years was -$678000.0 (2023), compared with a mean of -$513941.2.
  • Peak annual rise in Change in Receivables hit 2975.0% in 2020, while the deepest fall reached 1264.32% in 2020.
  • Revolution Medicines' Change in Receivables stood at -$2.9 million in 2020, then soared by 48.97% to -$1.5 million in 2021, then soared by 82.0% to -$267000.0 in 2022, then surged by 453.93% to $945000.0 in 2023, then crashed by 232.7% to -$1.3 million in 2024.
  • The last three reported values for Change in Receivables were -$1.3 million (Q1 2024), $945000.0 (Q4 2023), and -$2.2 million (Q3 2023) per Business Quant data.